GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
=== Magnetotaxis === The movement and orientation of "Ca. M. multicellularis" appears to be altered by many external stimuli as it undergoes magnetotaxis, photokinesis, negative phototaxis and potentially helical klinotaxis. The organism contains multiple internal magnetosomes, membrane-bound structures containing magnetic nanocrystals. In "Ca. M. multicellularis" these crystals are greigite (Fe3S4) but in most other species of multicellular magnetotactic bacteria (MMB) the crystals are magnetite (Fe3O4). These magnetosomes are organised in linear chains that allow the consortium to orient itself along the Earth's geomagnetic field. In samples from the Southern Hemisphere, "Ca. M. multicellularis" exhibits a preference for south-facing orientation while swimming. In weak magnetic fields, under 80 μT, "Ca. M. multicellularis" behaves differently to other magnetotactic bacteria. Under fields close to or weaker than Earth's geomagnetic field, its trajectories appear significantly scattered away from the exact magnetic field line. In these situations, movement relies mostly on a combination of other environmental factors and the direction of the magnetic field line does not fully control the final swimming direction.
==== Weak partial androgenic activity ==== CPA, like spironolactone and other steroidal antiandrogens such as chlormadinone acetate and megestrol acetate, is actually not a pure antagonist of the AR – that is, a silent antagonist – but rather appears to be a very weak partial agonist. Clinically, CPA generally functions purely as an antiandrogen, as it displaces much more efficacious endogenous androgens such as testosterone and DHT from interacting with the receptor and thus its net effect is virtually always to lower physiological androgenic activity. But unlike silent antagonists of the AR like nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide, CPA, by virtue of its slight intrinsic activity at the AR, may be unable to fully inhibit androgenic signaling in the body, which may persist to an extent in some tissues such as the prostate gland. In accordance with its albeit weak capacity for activation of the AR, CPA has been found to stimulate androgen-sensitive carcinoma growth in the absence of other androgens, an effect which could be blocked by co-treatment with flutamide. In one study in rodents, DHT-stimulated prostate weight remained 40% above controls with administration of CPA even at the highest dosage, while flutamide was able to completely block the stimulatory effects of DHT. In addition, CPA alone increased prostate weight by 60%, whereas flutamide had no effect.
== History == Setmelanotide was invented at Ipsen. It was initially known as BIM-22493 and then as RM-493 and IRC-022493. It was evaluated in two one-year clinical studies. The first study enrolled 10 participants with obesity and confirmed or suspected POMC or PCSK1 deficiency while the second study enrolled 11 participants with obesity and confirmed or suspected LEPR deficiency; all participants were six years or older. Most participants had lost more than 10% of their initial body weight after a year of treatment. Some participants also reported feeling less hungry. The U.S. Food and Drug Administration (FDA) granted the application for setmelanotide orphan disease designation, breakthrough therapy designation, and priority review. The FDA granted the approval of Imcivree to Rhythm Pharmaceutical, Inc.
== Prognosis == Prognosis depends on the condition itself. Some conditions such as MS depend on the subtype of the disease and various attributes of the patient such as age, sex, initial symptoms, and the degree of disability the patient experiences. Life expectancy in MS patients is 5 to 10 years lower than unaffected people. MS is an inflammatory demyelinating disease of the central nervous system (CNS) that develops in genetically susceptible individuals after exposure to unknown environmental trigger(s). The bases for MS are unknown but are strongly suspected to involve immune reactions against autoantigens, particularly myelin proteins. The most accepted hypothesis is that dialogue between T-cell receptors and myelin antigens leads to an immune attack on the myelin-oligodendrocyte complex. These interactions between active T cells and myelin antigens provoke a massive destructive inflammatory response and promote continuing proliferation of T and B cells and macrophage activation, which sustains secretion of inflammatory mediators. Other conditions such as central pontine myelinolysis have about a third of patients recover and the other two-thirds experience varying degrees of disability. In some cases, such as transverse myelitis, the patient can begin recovery as early as 2 to 12 weeks after the onset of the condition.
== V == Lauri Vaska (1925–2015), Estonian/American chemist Louis Nicolas Vauquelin (1763–1829), French pharmacist and chemist, discovered the elements beryllium and chromium Vincent du Vigneaud (1901–1978), 1955 Nobel Prize in Chemistry Artturi Ilmari Virtanen (1895–1973), chemist, Nobel Prize laureate Max Volmer, Germany (1885–1965) Alessandro Volta (1745–1827), Italian electrochemist, invented the voltaic cell Alexander Vinogradov (1895-1975), Soviet geochemist
Sources: en.wikipedia.org
Peritoneal ligament: a fold of peritoneum or other membranes. Fetal remnant ligament: the remnants of a fetal tubular structure. Periodontal ligament: a group of fibers that attach the cementum of teeth to the surrounding alveolar bone.
Works by Michel Eugène Chevreul at Project Gutenberg (The laws of contrast of colour) Obituary in: "Obituary Notes" . Popular Science Monthly. Vol. 35. June 1889. Chevreul on cyberlipid.org Paper on Chevreul's life-long work on colour contrast by Prof Georges Roque, Paris Chevreul's (1861) Exposé d’un moyen de définir et de nommer les couleurs. Atlas - digital facsimile from the Linda Hall Library Chevreul's (1888) Des couleurs et de leurs applications aux arts industriels à l'aide des cercles chromatiques - digital facsimile from the Linda Hall Library
13,000, 30 October 2006 – The SENSEX on 30 October 2006 crossed 13,000 mark for the first time, touching a peak of 13,039.36, before closing at 13,024.26 points. It took 135 days to reach 13,000 from 12,000, and 124 days to reach 13,000 from 12,500. 14,000, 5 December 2006 – The SENSEX on 5 December 2006 crossed 14,000 mark for the first time, after opening the day with a peak of 14,028 at 9.58 am (IST).
Acetate CH3COO− (acetic acid) Carbonate CO2−3 (carbonic acid) Chloride Cl− (hydrochloric acid) Citrate HOC(COO−)(CH2COO−)2 (citric acid) Cyanide C≡N− (hydrocyanic acid) Fluoride F− (hydrofluoric acid) Nitrate NO−3 (nitric acid) Nitrite NO−2 (nitrous acid) Oxide O2− (water) Phosphate PO3−4 (phosphoric acid) Sulfate SO2−4 (sulfuric acid) Salts with varying number of hydrogen atoms replaced by cations as compared to their parent acid can be referred to as monobasic, dibasic, or tribasic, identifying that one, two, or three hydrogen atoms have been replaced; polybasic salts refer to those with more than one hydrogen atom replaced. Examples include:
Sources: en.wikipedia.org
Therefore, the essence of PseAAC is that on one hand it covers the AA composition, but on the other hand it contains the information beyond the AA composition and hence can better reflect the feature of a protein sequence through a discrete model. Meanwhile, various modes to formulate the PseAAC vector have also been developed, as summarized in a 2009 review article.
==== Pulmonary tissues ==== Lung tissue engineering focuses on developing functional respiratory structures to treat end-stage pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Due to the complex, highly vascularized three-dimensional architecture of the lung, which comprises over forty distinct cell types and a delicate alveolar-capillary basement membrane, whole-organ biofabrication typically relies on decellularized donor lung scaffolds. This process strips away immunogenic cellular material while preserving the native extracellular matrix geometry and mechanical compliance required for ventilation. Research strategies prioritize the multi-lineage recellularization of these scaffolds using patient-specific induced pluripotent stem cells (iPSCs) differentiated into alveolar epithelial cells (type I and II) and microvascular endothelial cells. Additionally, biomimetic microfluidic platforms, or "lung-on-a-chip" models, are utilized to study cellular shear stress and gas-exchange dynamics, serving as precursors to transplantable bioartificial lung devices.
α-Methylthiofentanyl is an opioid analgesic that is an analogue of fentanyl. α-Methylthiofentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared. α-Methylthiofentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
When a DU penetrator reaches the interior of an armored vehicle, it catches fire, often igniting ammunition and fuel and possibly causing the vehicle to explode. DU is used by the U.S. Army in 120 mm or 105 mm cannons employed on the M1 Abrams tank. The DU content in various ammunition is 180 grams (6.3 oz) in 20 mm, 200 grams (7.1 oz) in 25 mm, 280 grams (9.9 oz) in 30 mm, 3.5 kilograms (7.7 lb) in 105 mm, and 4.5 kilograms (9.9 lb) in 120 mm penetrators. DU was used during the mid-1990s in the U.S. to make hand grenades, and land mines, but those applications have been discontinued, according to Alliant Techsystems. The US Navy used DU in its 20 mm Phalanx CIWS guns, but switched in the late 1990s to armor-piercing tungsten. Only the US and the UK have acknowledged using DU weapons. The Soviet Union and Russia have used DU weaponry since the 3BM-32 Vant, designed for the 125 mm tank cannons. In 2018, TASS reported that Russia was arming some of its T-80 models with 3BM60 Svinets-2 DU rounds. 782,414 DU rounds were fired during the 1991 war in Iraq, mostly by US forces. In a three-week period of conflict in Iraq during 2003, it was estimated that between 1,000 and 2,000 tonnes of depleted uranium munitions were used. More than 300,000 DU rounds were fired during the 2003 war, the vast majority by US troops.
=== Other procedures === More recent approaches to the synthesis of N-substituted isatins involves the direct oxidation of commercially available, substituted indoles or oxindoles with different oxidizing agents such as TBHP, IBX-SO3K, tBuONO etc.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.